Alnylam and BridgeBio are competing for people who are switching from Pfizer’s blockbuster ATTR amyloidosis drug tafamidis while all three companies are fighting for new patients.
Pfizer Mounts Defense of Cardiac Blockbuster as Alnylam, BridgeBio Enter Market